. 2019 Jul 19;40(6):1573–1604. doi: 10.1210/er.2019-00007

Table 1.

Characteristics of RAI-Refractory Thyroid Cancer

Any one of the following meets the criteria for RAI-refractory DTC:

• Lack of RAI uptake in all tumors upon a diagnostic whole-body scan or on a posttreatment scan after a treatment dose of ¹³¹I in a patient with known structural disease

• Progression of disease within 6–12 mo after treatment with ¹³¹I

• Progression of disease in a patient who has received ≥600 mCi of ¹³¹I

See (10, 41, 42).